The GLP-1 Gold Rush Is Entering Its Enforcement Phase

For the last several years, GLP-1 drugs have reshaped the weight-loss, telehealth, med spa, and direct-to-consumer healthcare markets. Semaglutide, tirzepatide, liraglutide, and related drugs created enormous patient demand. Drug shortages created room for compounding. Telehealth companies made access faster. Med spas and wellness clinics built new service lines. Pharmacies found themselves in the middle of one of the most commercially important healthcare trends in the country.

That phase is now changing.

The GLP-1 market is no longer just a story about demand, access, and affordability. It is becoming a story about FDA enforcement, compounding limits, marketing claims, product sourcing, patient-specific documentation, and litigation by brand manufacturers.

In plain English: the GLP-1 gold rush is entering its enforcement phase.

What Changed?

The biggest mistake companies can make right now is assuming that GLP-1 compliance is still only about whether a drug is "in shortage." That was never the whole analysis, and it is now clearly inadequate.

FDA's recent actions show a broader enforcement theory. FDA is focused on whether compounded GLP-1 products are being marketed as if they are FDA-approved drugs, whether companies are implying that compounded products are generic or equivalent to branded drugs, whether compounded formulations are truly patient-specific, whether additives are being used as a legal workaround, and whether the supply chain can support the quality and safety representations being made to patients.

FDA's Office of Compliance reported that, in 2025, it issued 58 warning letters to telehealth companies selling misbranded compounded products where advertising or promotion allegedly implied that unapproved compounded products had been FDA-approved or obscured important differences between compounded drugs and FDA-approved medications.

That is the backdrop. The more recent FDA actions sharpen the point.

The First Tranche: Misleading Advertising Became the Target

In September 2025, FDA announced a broader crackdown on deceptive direct-to-consumer pharmaceutical advertising. FDA stated that it was sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads. FDA also emphasized that digital and social media advertising, including influencer promotion, had blurred the line between evidence-based information and promotional material.

That matters for GLP-1 companies because many of these business models are marketing-driven. The patient often does not start with a local physician or pharmacy. The patient starts with a Google search, TikTok video, Instagram ad, landing page, online quiz, or subscription checkout flow.

FDA's position is not subtle. Compounded drugs are not FDA-approved, and compounded drugs are not the same as FDA-approved generics. FDA has expressly identified claims implying sameness with FDA-approved products as a primary violation in its GLP-1 warning letters.

This is why phrases like "generic Ozempic," "generic Wegovy," "same as Mounjaro," "same active ingredient," "clinically proven," or "FDA-approved ingredient" are legally dangerous when used to sell or promote compounded GLP-1 products.

The Second Tranche: FDA Expanded From Marketing to Product Integrity and Safety

In February 2026, FDA updated its public concerns regarding unapproved GLP-1 drugs used for weight loss. This was not only about website copy. FDA identified concerns involving improper storage during shipping, questionable imported GLP-1 APIs, fraudulent compounded products, dosing errors, adverse events, semaglutide salt forms, and products falsely labeled "for research purposes" or "not for human consumption."

That update is important because it moves the issue from "Did the website say something too aggressive?" to "Can the company actually defend the product, the supply chain, the dosing, the pharmacy relationship, and the patient instructions?"

FDA also stated that retatrutide and cagrilintide cannot be used in compounding under federal law and that semaglutide sodium and semaglutide acetate are different active ingredients than those used in approved drugs, with FDA stating it was not aware of any lawful basis for their use in compounding.

For med spas, telehealth companies, MSOs, and pharmacies, that should be a major warning. GLP-1 compliance is not just a marketing review. It is vendor diligence, pharmacy diligence, API diligence, label review, shipping review, adverse event procedures, prescription documentation, and patient education.

The Third Tranche: Telehealth Branding Became a Specific Enforcement Issue

On March 3, 2026, FDA announced 30 warning letters to telehealth companies for allegedly making false or misleading claims regarding compounded GLP-1 products offered on their websites. FDA described this as the second group of warning letters sent to telehealth firms since the September 2025 advertising crackdown.

FDA identified two particularly important categories of violations: claims implying sameness with FDA-approved products, and product sourcing claims that allegedly obscured who actually compounded the drug. In one warning letter, FDA objected to compounded semaglutide and tirzepatide products displayed with the telehealth company's name on the pictured label, suggesting that the telehealth company was the compounder when FDA said it was not. FDA also objected to claims such as "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®."

That is a very practical warning. Many GLP-1 companies try to build a clean consumer brand around a product they do not manufacture, compound, dispense, or clinically control. That branding strategy may help conversion rates, but it can also create regulatory risk if the patient is misled about who is providing medical services, who is compounding the drug, whether the product is FDA-approved, or how the product compares to branded drugs.

The Legal Issue Is Not "Compounding Is Illegal"

The stronger and more accurate point is this: the defensible pathway has narrowed.

Compounding is not automatically unlawful. Federal law expressly recognizes pharmacy compounding and outsourcing facilities. But those pathways have conditions. The statutory text matters.

For traditional 503A compounding, the statute says the compounder must not compound "regularly or in inordinate amounts" drug products that are "essentially copies" of commercially available drug products.

For 503B outsourcing facilities, the statute says the facility may not compound using bulk drug substances unless the substance appears on FDA's clinical-need list or the compounded drug appears on FDA's shortage list at the time of compounding, distribution, and dispensing.

That is the legal center of the current fight. The question is not whether patients want less expensive GLP-1 access. Of course they do. The question is whether a particular compounded GLP-1 program fits within the limited legal pathways that Congress and FDA recognize.

FDA's April 2026 Guidance Made the "Additive Strategy" Harder to Defend

For many GLP-1 programs, the theory has been some version of this: add vitamin B12, glycine, niacinamide, pyridoxine, or another ingredient, then argue the drug is no longer a copy.

FDA's April 1, 2026 clarification makes that strategy much harder to rely on as a general business model.

FDA stated that, under section 503A, a compounded drug product may be treated as essentially a copy if it has the same API as the commercially available drug product in the same, similar, or easily substitutable strength and can be used by the same route of administration, unless the prescriber determines and documents a significant difference for the identified individual patient. FDA also addressed combination products, stating that a compounded product combining semaglutide API with another API, such as vitamin B12, may still be considered essentially a copy when the drug products use the same route and the strengths are within 10% of the respective commercially available drug products.

That does not mean every compounded GLP-1 formulation is unlawful. It does mean that the analysis needs to be patient-specific, clinically real, and documented. A mass-market formulation change designed primarily to preserve a business model is not the same thing as a prescriber determining that an identified patient needs a specific compounded formulation because the commercially available drug does not meet that patient's medical needs.

That distinction is now where much of the legal risk sits.

FDA Is Also Moving Against Large-Scale 503B GLP-1 Compounding From Bulk API

On April 30, 2026, FDA announced that it was proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound those drugs from bulk substances.

The Federal Register notice is even more important because FDA explained how it views "clinical need." FDA stated that it does not interpret supply issues, backorders, convenience, or lower cost as clinical need for purposes of the 503B bulks list. FDA also proposed not to include semaglutide, tirzepatide, and liraglutide on that list.

That is a major development. It does not eliminate every possible patient-specific 503A compounding pathway. But it does put pressure on large-scale GLP-1 compounding models that rely on bulk API and broad consumer demand rather than individualized clinical need.

Manufacturer Litigation Is Now Part of the Regulatory Environment

FDA is not the only actor shaping the market. Novo Nordisk and Eli Lilly have been using litigation to challenge companies selling or promoting compounded versions of GLP-1 drugs.

The Eli Lilly v. Mochi Health litigation is especially instructive. In April 2026, the federal court allowed portions of Lilly's case to proceed. Lilly alleged, among other things, that Mochi misrepresented compounded tirzepatide as safe and effective based on studies of Lilly's products, misrepresented products as FDA-approved, and claimed its compounded tirzepatide was "personalized." The court found that Lilly plausibly alleged Lanham Act standing and allowed false advertising theories tied to safety representations and "personalized" medicine claims to proceed past dismissal.

The court's discussion is important because it shows how "personalized medicine" claims can create litigation exposure. It is one thing to say that a prescriber may determine a patient needs a compounded formulation. It is another thing to build a mass-market advertising campaign around "customized" or "personalized" GLP-1s if the actual formulation changes are driven by pharmacy relationships, supply, pricing, or business considerations rather than individualized clinical need.

The Hims & Hers/Novo Nordisk development points in the same direction. In March 2026, Hims & Hers announced a collaboration with Novo Nordisk, stated that it would no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and said existing patients would have the opportunity to transition to FDA-approved medicines where clinically appropriate. The company also stated that Novo Nordisk was dismissing its lawsuit without prejudice.

That is not just a business story. It is a compliance signal. The market is moving from "find a compounder and advertise access" toward "offer FDA-approved products where available, and reserve compounding for narrower, clinically documented circumstances."

What GLP-1 Companies Should Do Now

Companies involved in GLP-1 programs should treat this as a full compliance reset.

A telehealth company should review its website, landing pages, intake flows, patient FAQs, text messages, emails, ads, influencer content, and brand-name references. The question is not only whether the company has a disclaimer. The question is whether the overall impression suggests that a compounded product is FDA-approved, generic, equivalent, clinically proven based on branded-drug studies, or sourced from the telehealth company itself.

A med spa or wellness clinic should review whether it is clearly distinguishing medical services, pharmacy services, and management or administrative services. Patients should understand who is providing clinical care, who is prescribing, who is dispensing or compounding, and whether the medication is FDA-approved or compounded.

A pharmacy or outsourcing facility should review whether its GLP-1 compounding pathway still fits within 503A or 503B, whether the product is essentially a copy, whether bulk API is permissible, whether certificates of analysis and sourcing documentation are sufficient, and whether any additives are supported by a real patient-specific rationale.

An MSO should be especially careful. The MSO should not appear to be making clinical decisions, selecting formulations for business reasons, directing providers to prescribe compounded products, controlling pharmacy selection in a way that undermines patient choice, or making patient-facing claims that belong to a professional entity or pharmacy.

The Bottom Line

The GLP-1 gold rush is not over. But the easy phase is.

For a while, companies could rely on shortage conditions, patient demand, affordability, and aggressive online marketing to build GLP-1 programs quickly. That environment has changed. FDA is now scrutinizing advertising, sourcing, labeling, dosing, shipping, API quality, and the legal basis for compounding. Manufacturers are using litigation to attack claims of equivalence, safety, FDA approval, and personalization. The "just add B12" approach is no longer a serious legal strategy unless it is tied to documented, patient-specific clinical need.

The companies that survive the next phase will be the ones that can explain their model clearly: who provides the medical care, who compounds or dispenses the drug, why the product is compounded, why the formulation is appropriate for the patient, how the company avoids misleading marketing, and how it protects patient choice and clinical independence.

GLP-1s remain one of the most important areas in healthcare. But from this point forward, GLP-1 growth needs to be built on compliance, not just demand.

FAQs

Are compounded GLP-1 drugs FDA-approved?

No. FDA states that compounded drugs are not FDA-approved and that FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.

Can a company advertise compounded semaglutide as generic Ozempic or generic Wegovy?

That is high risk. FDA has objected to claims implying that compounded GLP-1 drugs are the same as, generic versions of, or clinically proven like FDA-approved drugs.

Does adding vitamin B12 or another ingredient make compounded semaglutide lawful?

Not automatically. FDA has stated that a compounded product combining semaglutide with another API, such as vitamin B12, may still be considered essentially a copy depending on route, strength, and whether there is documented patient-specific significant difference.

What is the biggest GLP-1 compliance risk for telehealth companies?

The biggest risk is usually the combination of aggressive marketing, unclear product sourcing, weak patient-specific documentation, and branding that makes a compounded product look FDA-approved, generic, equivalent, or controlled by the telehealth platform. FDA's March 2026 warning letters specifically targeted false or misleading telehealth claims regarding compounded GLP-1 products.

*Disclaimer: This article is intended for informational purposes only and is not legal advice or a substitute for consultation with a licensed legal professional in a particular case or circumstance. Readers should not act upon information in this article without professional counsel. This material may be considered advertising under certain rules of professional conduct.